These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 23467454)

  • 1. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance.
    Zanger UM; Klein K
    Front Genet; 2013; 4():24. PubMed ID: 23467454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncoupling of Cytochrome P450 2B6 and stimulation of reactive oxygen species production in pharmacogenomic alleles affected by interethnic variability.
    Yamoune S; Müller JP; Langmia IM; Scholl C; Stingl JC
    Biochim Biophys Acta Gen Subj; 2024 May; 1868(5):130595. PubMed ID: 38467309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
    Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
    Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
    Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
    Zanger UM; Klein K; Saussele T; Blievernicht J; Hofmann MH; Schwab M
    Pharmacogenomics; 2007 Jul; 8(7):743-59. PubMed ID: 17638512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P450 2B6: function, genetics, and clinical relevance.
    Turpeinen M; Zanger UM
    Drug Metabol Drug Interact; 2012; 27(4):185-97. PubMed ID: 23152403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.
    Hofmann MH; Blievernicht JK; Klein K; Saussele T; Schaeffeler E; Schwab M; Zanger UM
    J Pharmacol Exp Ther; 2008 Apr; 325(1):284-92. PubMed ID: 18171905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.
    Talakad JC; Kumar S; Halpert JR
    Drug Metab Dispos; 2009 Mar; 37(3):644-50. PubMed ID: 19074527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.
    Ariyoshi N; Ohara M; Kaneko M; Afuso S; Kumamoto T; Nakamura H; Ishii I; Ishikawa T; Kitada M
    Drug Metab Dispos; 2011 Nov; 39(11):2045-8. PubMed ID: 21821736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
    Wang PF; Neiner A; Kharasch ED
    Drug Metab Dispos; 2019 Oct; 47(10):1195-1205. PubMed ID: 31324697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
    Wang PF; Sharma A; Montana M; Neiner A; Juriga L; Reddy KN; Tallchief D; Blood J; Kharasch ED
    Br J Clin Pharmacol; 2022 Nov; 88(11):4881-4893. PubMed ID: 35538637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.
    Zhang H; Sridar C; Kenaan C; Amunugama H; Ballou DP; Hollenberg PF
    J Pharmacol Exp Ther; 2011 Sep; 338(3):803-9. PubMed ID: 21659470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation.
    Watanabe T; Saito T; Rico EMG; Hishinuma E; Kumondai M; Maekawa M; Oda A; Saigusa D; Saito S; Yasuda J; Nagasaki M; Minegishi N; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
    Biochem Pharmacol; 2018 Oct; 156():420-430. PubMed ID: 30201214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
    Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
    HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
    Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
    Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants.
    Wang PF; Neiner A; Kharasch ED
    Drug Metab Dispos; 2020 Jun; 48(6):438-445. PubMed ID: 32238417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
    Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
    Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme.
    Wang H; Tompkins LM
    Curr Drug Metab; 2008 Sep; 9(7):598-610. PubMed ID: 18781911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allelic and genotype frequencies of major CYP2B6 polymorphisms in the Pakistani population.
    Ahmed S; Khan S; Janjua K; Imran I; Khan AU
    Mol Genet Genomic Med; 2021 Mar; 9(3):e1527. PubMed ID: 33599403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
    Lv J; Hu L; Zhuo W; Zhang C; Zhou H; Fan L
    Pharmacogenet Genomics; 2016 Feb; 26(2):80-7. PubMed ID: 26580670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.